---
source_pdf: "https://drive.google.com/file/d/1MNOzmLs3s81L1Ir8dhsq36ScgjumNpie/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "210120 Clarify - Investor Deck.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1MNOzmLs3s81L1Ir8dhsq36ScgjumNpie/view)

# Clarify Health Solutions Pitch Deck

## Slide 1: Healthcare's Enterprise Analytics Platform

✓ Clarify
HEALTH
SOLUTIONS
HEALTHCARE'S ENTERPRISE
ANALYTICS PLATFORM

## Slide 2: We empower our customers to deliver better care and therapies through actionable insights

We empower our customers to deliver better care
and therapies through actionable insights
Clarify

## Slide 3: Our fractured US healthcare system wastes $1T+ annually

Our fractured US healthcare system wastes $1T+ annually

*   **Highly variable outcomes**
*   **Poor service and experience**
*   **Physician burnout and dissatisfaction**
*   **30% wasted spend**

**Root cause is a lack of timely, precise, and actionable insights**

Confidential 3

## Slide 4: Too often, we continue to rely on 'art' and 'experience' for answers

Too often, we continue to rely on 'art' and 'experience' for answers

**Patients and Consumers**
*   What does this (diagnosis) mean for me?
*   What are my options?
*   Who is the right doctor for me?
*   Is this the right therapy?
*   How much will this cost?

**Health Systems and Physician Groups**
*   What are the needs of this patient?
*   Should I hire this doctor?
*   How and where can we grow?
*   How good are we, really? At what?
*   How can we improve?

**Health Insurers and Payers**
*   What are the needs of this member?
*   What will total medical cost be? Why?
*   Which doctors & hospitals should I contract with?
*   How do I best match members to the right care?

**Life Sciences Companies**
*   How does disease map & progress?
*   How do I maximize market share?
*   What is the true value-add of my therapy/drug?
*   How do I increase the success and reduce the cost of clinical trials?

| Category                          | Spend             | Description                                |
| :-------------------------------- | :---------------- | :----------------------------------------- |
| **$376B per year**                |                   | Out of pocket consumer healthcare spending |
| **$1,061B per year**              |                   | Total spend across all U.S. hospitals      |
| **$1,200B per year**              |                   | Commercial insurer spend on medical claims |
| **$345B per year**                |                   | U.S. prescription drug spend               |

Source: Center for Medicare and Medicaid Services (CMS), American Hospital Association (AHA)
Confidential 4

## Slide 5: Clarify delivers a ground-breaking enterprise analytics platform

Clarify delivers a ground-breaking enterprise analytics platform

**Fast, cutting-edge data science**

**Patented SaaS platform adapted from financial services**

**Trusted suite of products answers the critical questions**

**Comprehensive, patient-level data covering 300M+ Americans**

**Clinician adoption drives real change**

**(Image content)**
A screenshot of the Clarify Build Network application, showing a table of contracting entities, their scores, and metrics like efficiency, quality, and referral percentage.

**Network Score: 75 TOTAL SCORE**
*   Efficiency: 82
*   Quality: 73
*   Referral: 88

**Table: Contracting Entities (partial view)**

| Contracting Entity                   | Score | Efficiency Score | Cost Score | Quality Score | Referral Score | % | Patients | Providers |
| :----------------------------------- | :---- | :--------------- | :--------- | :------------ | :------------- | :- | :------- | :-------- |
| University of Washington Medicine    | 80    | 82               | 9%         | 12,289        | 9,021          | 100 | 482     |
| St. Joseph Medical Center            | 81    | 68               | 76         | 75            | 92             | 9,745 | 6,170   | 100 | 607 |
| Swedish Redmond Campus               | 74    | 77               | 70         | 60            | 998            | 3,721 | 100   | 39      |
| MultiCare Tacoma General Hospital    | 74    | 82               | 22         | 74            | 75             | 3% | 347     | 3,085   | 100 | 65 |
| Valley Medical Center                | 71    | 70               | 83         | 75            | 55             | 3% | 1,034   | 2,824   | 100 | 41 |
| Providence St. Peter Hospital        | 81    | 86               | 84         | 82            | 70             | 3% | 8,480   | 2,743   | 100 | 528 |
| CHI Franciscan Health                | 60    | 80               | 50         | 49            | 28             | 3% | 10,135  | 2,490   | 100 | 289 |
| Northwest Hospital & Medical Center  | 77    | 14               | 70         | 73            | 75             | 2% | 109     | 2,104   | 67    | 46    |
| St. Anthony Hospital                 | 64    | 77               | 79         | 77            | 24             | 2% | 4,532   | 1,546   | 100 | 178 |
| The Everett Clinic                   | 72    | 76               | 80         | 94            | 40             | 2% | 1,284   | 1,457   | 100 | 80 |
| Harborview Medical Center            | 80    | 82               | 72         | 74            | 90             | 2% | 201     | 1,380   | 100 | 6 |
| Swedish Medical Center - Edmonds Ca... | 63    | 76               | 78         | 48            | 50             | 1% | 201     | 1,380   | 100 | 6 |

Confidential 5

## Slide 6: Clarify's current products address a $5B+ market

Clarify's current products
address a $5B+ market

**Enterprise Analytics Platform**
Financial services-grade technology stack
with multiple business applications

*   DELIVERY
*   INTELLIGENCE
*   DATA & ARCHITECTURE

**Business Applications (SaaS) | TAM**

| Business Applications (SaaS) | TAM        |
| :--------------------------- | :--------- |
| Clarify Networks             | $1.5B+     |
| Clarify Care                 | $1.3B+     |
| Clarify Populations          | $0.5B+     |
| Clarify Value                | $0.3B+     |
| Clarify Growth               | $1.3B+     |

Confidential 6

## Slide 7: Industry leaders are rapidly adopting the platform

Industry leaders are rapidly adopting the platform

**Logos visible:**
*   Cleveland Clinic
*   Cigna
*   HIGHMARK
*   Horizon
*   Sutter Health
*   Celgene
*   SANOFI
*   NYP
*   Pfizer
*   CENTENE Corporation
*   CEDARS-SINAI
*   Oscar
*   NOVARTIS
*   Independence
*   MERCER
*   JOHN MUIR HEALTH

Confidential 7

## Slide 8: Rapid ARR growth

Rapid ARR growth

**Bar Chart: ARR Growth (millions, estimated)**

| Fiscal Year | ARR (millions) |
| :---------- | :------------- |
| FY19A       | 2              |
| FY20A       | 6              |
| FY21E       | 21 - 23        |
| FY22E       | 46             |

Current FY: FY21E

**Key Metrics:**
*   **$425k** Average Customer Size
*   **5.6** FQ3 21 LTV : CAC Ratio
*   **150%** FY21 Net Revenue Retention
*   **$106m** Total Open Pipeline

Note: Fiscal year ends Jan 31
Confidential 8

## Slide 9: Path to $46m ARR in FY22

Path to
$46m ARR
in FY22

**Table: Income Statement**
($ in thousands, Fiscal Year end 1/31)

|                                             | FQ1 22      | FQ2 22      | FQ3 22      | FQ4 22      | FY2022      |
| :------------------------------------------ | :---------- | :---------- | :---------- | :---------- | :---------- |
| **Beginning Contracted ARR**                | **$23,000** | **$27,152** | **$32,994** | **$39,000** | **$23,000** |
| New Customer ARR                            | 3,570       | 4,463       | 4,463       | 5,355       | 17,850      |
| Upsell ARR                                  | 1,530       | 1,913       | 1,913       | 2,295       | 7,650       |
| Churn/Contraction                           | (948)       | (533)       | (369)       | (650)       | (2,500)     |
| **Ending Contracted ARR**                   | **$27,152** | **$32,994** | **$39,000** | **$46,000** | **$46,000** |
| Growth                                      | 205%        | 193%        | 124%        | 100%        | 100%        |
| Exit ARR (MRR * 12)                         | $17,733     | $22,400     | $27,846     | $33,571     | $33,571     |
| Software Subscription Revenue               | 3,773       | 5,085       | 6,359       | 7,783       | 23,000      |
| Professional Services & Implementation Revenue | 1,247       | 1,000       | 1,250       | 1,250       | 4,747       |
| **Total Revenue Recognized**                | **$5,020**  | **$6,085**  | **$7,609**  | **$9,033**  | **$27,747** |
| Cost of Sales (excluding amortization)      | 1,246       | 1,411       | 1,591       | 1,573       | 5,821       |
| Margin                                      | 25%         | 23%         | 21%         | 17%         | 21%         |
| **Adj. Gross Profit**                       | **3,774**   | **4,674**   | **6,018**   | **7,460**   | **21,926**  |
| Margin                                      | 75%         | 77%         | 79%         | 83%         | 79%         |
| Sales & Marketing                           | 4,577       | 4,888       | 5,627       | 5,664       | 20,756      |
| Margin                                      | 91%         | 80%         | 74%         | 63%         | 75%         |
| Research & Development                      | 4,433       | 4,566       | 4,605       | 4,607       | 18,210      |
| Margin                                      | 88%         | 75%         | 61%         | 51%         | 66%         |
| G&A                                         | 1,442       | 1,704       | 1,781       | 1,772       | 6,699       |
| Margin                                      | 29%         | 28%         | 23%         | 20%         | 24%         |
| Total Opex                                  | 10,452      | 11,158      | 12,012      | 12,043      | 45,666      |
| Margin                                      | 208%        | 183%        | 158%        | 133%        | 165%        |
| **EBITDA**                                  | **($6,678)** | **($6,484)** | **($5,994)** | **($4,583)** | **($23,740)** |
| Margin                                      | (133%)      | (107%)      | (79%)       | (51%)       | (86%)       |

Note: ARR = Annual Recurring Revenue (cumulative across years)
Confidential 9

## Slide 10: Rapidly realizing the full leverage of the platform

Rapidly realizing the full leverage of the platform

**SaaS sales growth driving impressive metrics...**

**...paired with modest associated expenses**

**Line Chart: ARR per FTE ($m)**

| Fiscal Year | ARR per FTE ($m) |
| :---------- | :--------------- |
| FY20        | 40               |
| FY21        | 183              |
| FY22        | 279              |

**Line Chart: Adj. GM¹ (%)**

| Fiscal Year | Adj. GM¹ (%) |
| :---------- | :----------- |
| FY20        | 38           |
| FY21        | 55           |
| FY22        | 79           |

**Line Chart: Annual Net Burn ($m)**

| Fiscal Year | Annual Net Burn ($m) |
| :---------- | :------------------- |
| FY20        | 49                   |
| FY21        | 38                   |
| FY22        | 25                   |

**Line Chart: Burn Multiple²**

| Fiscal Year | Burn Multiple² |
| :---------- | :------------- |
| FY20        | 11.8           |
| FY21        | 2.2            |
| FY22        | 1.1            |

1.  Adjusted Gross Margin excluding amortization
2.  Net Cash Burn / Net New ARR

Confidential 10

## Slide 11: Delighted customers

Delighted customers

**Net Promoter Score (NPS)**
**42**
Industry Benchmarks:
Healthcare: 27
SaaS: 30

**Customer Satisfaction Score (CSAT)**
**4.3**
Industry Benchmarks:
Healthcare: 3.8
SaaS: 4.0

**Customer Testimonials:**

*   "This is the kind of insight I've been wanting to deliver for a decade"
*   "Clarify is an excellent business partner and truly provides advanced analytics"
*   "This is the 1st time having a data-driven way to see how many patients match criteria"
*   "We had no idea that 50% of our potential patients would not have access to our infusion therapy"

Confidential 11

## Slide 12: Proven land & expand impact at multiple customers

Proven land & expand impact at multiple customers

**Cigna**
*   **Jul '19 – $400K** to distinguish care variation across member types
*   **Feb '20 – $300K** to drive Center of Excellence hospital assessments
*   **Apr '20 – $370K** for population risk assessment software
*   **Apr '20 - $360K** to better match members & high value providers
*   **Jul-Aug '20 – $1.5M** for Networks, Care, and Risk software for Medicare and Individual LOBS

**Highmark**
*   **Jan '20 – $500k** lighthouse deal focused on PCP total cost of care in Highmark's MA plan and identifying risk drivers and trends (incl. clinical and SBDOH) across Highmark's member population
*   **Jan '21 - $2.1m** for access to quality analytics software for provider performance across 3m members
*   **Feb ‘21 – $600k** expansion of Populations product to other disease areas and Networks

**Novartis**
*   **Dec '19 – $650K** for analytics-driven identification of difficult-to-find patient populations & treating physicians to support launch of disease-modifying sickle cell therapeutic
*   **Jan '20 - $200K** for software demonstrating real-world efficacy of sickle cell therapeutics
*   **Feb '21 (exp.) – $775k** for software used to explore new markets for BD&L team

**Pfizer**
*   **Aug '19 – $145K** to further assess disease burden for ATTR-CM² in Medicaid LTSS³ population
*   **Sep '19 - $129K** for software with ATTR-CM² Medicare-focused prevalence & incidence insights
*   **Jan '20 – $559K** for adv. analytics software to answer Rare Diseases BU research questions across therapeutics
*   **Aug-Dec '20 – $300K+** upsells to provide more advanced analytics

1.  Chief Strategy Officer.
2.  ATTR-CM: Transthyretin amyloid cardiomyopathy, rare and fatal heart disease.
3.  LTSS: Long Term Support and Services
Note: All dollar amounts shown in bookings (contracted annual recurring revenues plus one-time fees)
Confidential 12

## Slide 13: Differentiated by speed and actionability at scale

Differentiated by speed and actionability at scale

**Scalable value delivery across your enterprise**
*   Single platform with multiple proven point solutions
*   Simplified implementation and business operations

**Enhanced intelligence from broadest dataset**
*   300M+ lives
*   Deep and broad dataset of Medicare, commercial, and Medicaid claims linked at the patient level
*   Incorporates SBDoH

**Actionable insights for immediate impact**
*   Modern tech stack from financial services
*   Rapid retrieval of data
*   Output in seconds, not weeks

**Transparency that drives clinician buy-in**
*   Case mix adjustment based on 400+ clinical and social factors
*   Fair, accurate and granular reporting that is easily interrogable

Confidential 13

## Slide 14: Clarify's linked data on 300 million+ individuals is one of the industry's largest

Clarify's linked data on 300 million+
individuals is one of the industry's largest

**Table: Data Sources Overview**

|                          | Government claims (Medicare)                                                                                                    | Managed Medicaid claims                                                              | Commercial claims                                                                                 | Clinical (EMR) data                                                                                                     | Prescriptions and dispensing                                                                                     | Social and behavioral data                                                                                             |
| :----------------------- | :------------------------------------------------------------------------------------------------------------------------------ | :----------------------------------------------------------------------------------- | :------------------------------------------------------------------------------------------------ | :---------------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------------------- |
| **Description**          | CMS QE and VRDC Innovator with 100% Medicare FFS data, and 100% MA and Medicaid for select years                                 | Tokenized claims (incl. medical and pharmacy) for large Managed Medicaid population  | Tokenized claims and remittance data, incl. Medicare Advantage population                         | Tokenized, EMR-derived clinical records (lab results, outcomes, treatments, and diagnoses)                              | Prescription data for majority of U.S. population; includes 100% Medicare FFS Part D data                        | Social determinant & consumer behavior data (SBDOH) with ~400 unique attributes per individual                       |
| **Annual lives**         | 40M annually                                                                                                                    | 29M annually                                                                         | 150M+ annually                                                                                    | 60M annually                                                                                                            | 90% of US population                                                                                             | Most of US population                                                                                                  |
| **Total lives**          | 54M                                                                                                                             | 58M                                                                                  | 250M+                                                                                             | 60M                                                                                                                     | 90% of US population                                                                                             | Most of US population                                                                                                  |
| **Longitudinal lives**   | 100%                                                                                                                            | 100%                                                                                 | 60%+                                                                                              | N/A                                                                                                                     | 85%+                                                                                                             | N/A                                                                                                                    |
| **Time frame**           | 2012 – present                                                                                                                  | 2015 – present                                                                       | 2014 – present                                                                                    | 2016 – present                                                                                                          | 2012 – present                                                                                                   | Varies                                                                                                                 |
| **Refresh frequency**    | Quarterly                                                                                                                       | Monthly                                                                              | Daily to Monthly                                                                                  | Monthly                                                                                                                 | Annual, on demand¹                                                                                               | Daily, on demand¹                                                                                                      |
| **Latency**              | ~10 months                                                                                                                      | 1-4 months                                                                           | 1-4 months                                                                                        | ~1 month                                                                                                                | 1-4 months                                                                                                       | Varies by Data Element                                                                                                 |

Confidential 14

## Slide 15: Clarify Networks for Payers and Risk-Bearing Providers

Clarify Networks for Payers and Risk-Bearing Providers
Efficiently and precisely optimize network performance using quality, cost and referral metrics

*   Select pre-populated geographic parameters, PCPs, specialists, and facilities via a guided design process
*   Drill down to see performance scores for every provider in the US, including PCPs, specialists and facilities, helping you quickly decide which ones to add or remove
*   View a network's expected performance scores as real-time design changes are made
*   Compare existing and exploratory networks on the fly to see how modifications impact performance

**Screenshot of Clarify Networks Application**

**Network Details**
Baseline: Seattle HMO Network
**TOTAL SCORE: 93**
*   Efficiency: 82
*   Quality: 73
*   Referral: 88

**Referral Details**
*   90 In Network Referral Scor
*   75 Out of Network Refe
*   45% In Network Res

**Network Totals**
*   8 Facilities
*   120 Total Providers
*   67 PCPs

**Table: Contracting Entities (partial view)**

| In Network | Contracting Entity                 | Score | Efficiency Score | Cost Score | Quality Score | Referral Score | % Patients | Providers |
| :--------- | :--------------------------------- | :---- | :--------------- | :--------- | :------------ | :------------- | :--------- | :-------- |
| ✔          | University Hospital                | 80    | 82               | 9          | 12,289        | 9,021          | 100        | 482       |
| ✔          | St. John's Medical Center          | 81    | 68               | 76         | 75            | 47             | 3,085      | 100       |
| ✔          | Swedish Hospital                   | 74    | 77               | 70         | 82            | 34             | 2,824      | 100       |
| ✔          | Bainbridge General Hospital        | 74    | 82               | 22         | 74            | 75             |            |           |
| ✔          | Valley Pacific Hospital            | 71    | 70               | 83         | 75            | 55             | 2,743      | 100       |
| O          | Providence Hospital                | 81    | 86               | 84         | 82            | 70             | 3%         |           |
| O          | St. Francis Health                 | 60    | 80               | 50         | 49            | 28             | 3%         | 10,135    | 100       |
| O          | Dr. Williams                       | 77    | 14               | 70         | 73            | 75             | 2%         | 109       | 100       |
| O          | Bay Physicians Group               | 64    | 77               | 79         | 77            | 24             | 2%         | 4,532     | 100       |
| O          | Everett Main Hospital              | 72    | 76               | 80         | 94            | 40             | 2%         | 1,284     | 100       |
| O          | Harbor Medical Center              | 80    | 82               | 72         | 74            | 90             | 2%         | 201       | 100       |
| O          | Finnish Hospital                   | 63    | 76               | 78         | 48            | 50             | 1%         | 201       | 100       |
| O          | Northwest Health Services          | 77    | 14               | 70         | 73            | 75             | 2%         | 109       | 100       |
| O          | St. Anthony Hospital               | 64    | 77               | 79         | 77            | 24             | 2%         | 4,532     | 100       |
| O          | The Everett Clinic                 | 72    | 76               | 80         | 94            | 40             | 2%         | 1,284     | 100       |
| O          | Harborview Medical Center          | 80    | 82               | 72         | 74            | 90             | 2%         | 201       | 100       |
| O          | Swedish Medical Center - Edmonds... | 63    | 76               | 78         | 48            | 50             | 1%         | 201       | 100       |

Confidential 15

## Slide 16: Clarify Care for Payers and Providers

Clarify Care for Payers and Providers
Reduce variation in care across providers, hospitals and post-acute facilities

*   Prioritize performance improvement areas across the continuum of care using AI
*   Identify the drivers of unwarranted variation across facilities, physicians, and spend categories
*   Compare performance between providers using advanced case mix adjusted benchmarks
*   Empower provider partners to confidently address clinical variation across all contracts and value-based programs

**Screenshot of Clarify Care Application**

**Primary Care: New York State Health System**
Summary | Efficiency | Quality | Scorecards

**Overall Performance Score**
Score Distribution of 2,678 PCPs

**Top Medical Groups**
*   91 First Medical Group
*   90 Hill Medical Collective
*   89 McGraw Health
*   85 Worthington Health
*   79 Stormbridge Medical

**Bottom Medical Groups**
*   91 Thromberg Health Group
*   90 Norton Medical Gre

**Inpatient Utilization**
*   **$18.4M** Opportunity to Reduce IP Utilization ↑ 2.6% since Q3
*   **32** IP Admits /1K ↓ 2.6% since Q3

**Emergency Dept. Uti**
*   **$13.2M** Oppty. to Reduce ED Utilization ↑ 2.6% since Q3

**Outpatient Labs & Imaging Use**
*   **$13.2M** Oppty. to Reduce OP Labs & Imaging ↑ 2.6% since Q3
*   **47** PCPs with Significant Use > Expected ↓ 2.6% since Q3

**Panel Management**
*   **86%** Annual Wellness
*   **3.1** ED:Urgent Care Ratio

**Quality & Compliance**
*   **85%** Flu Vaccine Rate
*   **56%** Breast Cancer Screen

Confidential 16

## Slide 17: Clarify Populations for Payers and Risk-Bearing Providers

Clarify Populations for Payers and Risk-Bearing Providers
Track and trend disease burden and utilization to get high-risk members the interventions they need

*   Quantify a member's risk level by linking their clinical and socioeconomic risk factors
*   Identify precise cohorts within your population with variation in spend and utilization
*   Predict increases in care utilization, by population, geography, and member
*   Reduce administration effort to develop, risk-stratify, and manage member outreach lists for engagement programs

**Screenshot of Clarify Populations Application**

**Population: Virginia**
Tri-State Area > Virginia
Summary | Chronic Conditions | Social Determinants | Utilization

**Social Determinants of Health**
*   Household Earnings
*   Wealth Stability
*   Housing Stability
*   Nearby Relatives
*   No Home Caregivers
*   No Household Vehicle

**Age and Gender**
*   0-34: 3%
*   35-44: 2%
*   45-54: 6%
*   55-59: 8%
*   60-64: 11%
*   65-69: 13%
*   70-74: 15%
*   75-79: 18%
*   80-84: 16%
*   85-89: 11%
*   90-94: 3%
*   95+: 1%

**Eligibility: 182K Members**
*   54% Commercial
*   26% Aged / Non Dual
*   8% Commercial Medicare Advantage
*   8% Aged / Dual
*   4% Disabled
*   <1% ESRD

**Chronic Condition Prevalence: Physical**

| Condition               | Opportunity | Prevalence |
| :---------------------- | :---------- | :--------- |
| Hypertension            | $18.3 M     | 53%        |
| Hyperlipidemia          | $10.5 M     | 40%        |
| Arthritis                | $8.5 M      | 31%        |
| Diabetes                | $21.5 M     | 27%        |
| Chronic Kidney Disease  | $20.6 M     | 24%        |
| Ischemic Heart Disease  | $11.4 M     | 23%        |
| Congestive Heart Failure | $2.1 M      | 14%        |
| COPD                    | $4.1 M      | 10%        |

**Chronic Condition Prevalence: Physical**

| Condition                         | Opportunity | Prevalence |
| :-------------------------------- | :---------- | :--------- |
| Depression                        | $3.2 M      | 16%        |
| Alzheimer's Disease & Related Dementia | $2.9 M      | 11%        |
| Drug / Substance Abuse            | $1.2 M      | 4%         |
| Alcohol Abuse                     | $0.8 M      | 3%         |
| Schizophrenia / Other Psychotic Disorders | $1.1 M      | 3%         |

Confidential 17

## Slide 18: Clarify Value for Providers

Clarify Value for Providers
Optimize participation structure and succeed in value-based models

*   Dynamic modelling of participation options with unprecedented speed
*   Best-in-class and transparent case-mix adjustment
*   Comprehensive cost, utilization, quality, and referral metrics

**Screenshot of Clarify Value Application**

**ACO Participant Selection**
Participating Providers | Facilities

**Network Details**
Attributed Patients: **98,351**

**PMPY Target Price: $11,936**

**PMPY Savings / (Losses): $43**

**Total Savings / (Losses): $4,191,292**

**Table: ACO Participant Selection - Next Generation ACO (partial view)**

| In Network | Contracting Entity     | # Attributed Patients | # PCPs | # APCs | Specialists | PMPY Benchmark | PMPY Observed | PMPY Savings / (Losses) | Total Savings / (Losses) | IP Admits per 1000 | Advanced Care Planning | Annual Wellness Visit |
| :--------- | :--------------------- | :-------------------- | :----- | :----- | :---------- | :------------- | :------------ | :---------------------- | :----------------------- | :----------------- | :--------------------- | :-------------------- |
| >          | Medical Group A        | 29,717                | 332    | 22     | 94          | $11,578        | $10,115       | $1,463                  | $43,484,292              | 42%                | 12%                    | 11                    |
| >          | Medical Group B        | 4,506                 | 22     | 8      | 22          | $11,697        | $17,429       | $(5,732)                | $(25,825,977)            | 30%                | 13%                    | 19                    |
| >          | Medical Group C        | 3,316                 | 23     | 2      | 19          | $11,459        | $12,391       | $(932)                  | $(3,090,576)             | 24%                | 12%                    | 21                    |
| >          | Medical Group D        | 3,551                 | 19     | 3      | 9           | $11,578        | $12,058       | $(480)                  | $(1,704,773)             | 31%                | 13%                    | 24                    |
| >          | Medical Group E        | 525                   | 2      | 0      | 0           | $11,339        | $9,279        | $2,061                  | $1,080,758               | 21%                | 10%                    | 25                    |
| >          | Medical Group F        | 5,695                 | 35     | 1      | 15          | $11,697        | $11,140       | $557                    | $3,173,943               | 29%                | 12%                    | 25                    |
| >          | Medical Group G        | 17,793                | 159    | 22     | 42          | $11,817        | $12,261       | $(445)                  | $(7,912,681)             | 29%                | 15%                    | 29                    |
| ✔          | Medical Group H        | 10,138                | 62     | 2      | 16          | $11,578        | $12,193       | $(615)                  | $(6,231,220)             | 35%                | 14%                    | 23                    |
| >          | Medical Group J        | 3,509                 | 17     | 5      | 4           | $11,339        | $11,935       | $(596)                  | $(2,091,066)             | 19%                | 15%                    | 20                    |
| >          | Medical Group K        | 13,838                | 74     | 1      | 42          | $11,697        | $11,239       | $459                    | $6,347,767               | 28%                | 12%                    | 24                    |
| >          | Medical Group L        | 5,767                 | 35     | 0      | 16          | $11,459        | $11,986       | $(527)                  | $(3,039,176)             | 27%                | 12%                    | 26                    |

Confidential 18

## Slide 19: Clarify Growth for Pharmaceutical Companies

Clarify Growth for Pharmaceutical Companies
Life Sciences analytics solution that unlocks value for therapy commercialization

*   **Build sub-cohorts**
    Iterate on patient cohorts with agility and precision to evaluate patient characteristics, and treatment & utilization history
*   **Sequence patient journeys**
    Characterize hard-to-identify patients based on chronologically sequenced patient journeys
*   **Map journeys to HCPs**
    Identify the primary decision maker and predict HCP likelihood to adopt based on past treatment sequences

**Screenshots of Clarify Growth Application**

**Performance in Key Cohorts**

| Cohort                          | Patients Altrabinmad Rx: Q4 Q3 | Q4 Rx % |
| :------------------------------ | :----------------------------- | :------ |
| 1 Prior ACE/ARB                 | 243                            | 5.6%    |
| 1 Prior ACE/ARB with CV Events  | 176                            | 4.7%    |
| 2-4 Prior ACE/ARBs              | 104                            | 14.6%   |
| 2-4 Prior ACE/ARBs with CV Events | 64                             | 23.4%   |

**Top Sequences Before Altrabinmad**

| Sequence           | Patients | Q4 | Q3 |
| :----------------- | :------- | :-- | :-- |
| Lisinopril         | 2,094    |    |    |
| Losartan           | 903      |    |    |
| Valsartan          | 301      |    |    |
| Enalipril          | 198      |    |    |
| Lisinopril > Losartan | 176      |    |    |

**Map journeys to HCPs (Physician view)**

| Physician           | Oppty Score | Patient Mix | Rx Behavior | Physician Traits |
| :------------------ | :---------- | :---------- | :---------- | :--------------- |
| Dunne, Thelonious   | 96          | 96          | 96          | 91               |
| Alexander, Evan     | 96          | 95          | 95          | 94               |
| Pena, Gladys        | 95          | 84          | 95          | 96               |
| Steward, Jorge      | 95          | 94          | 94          | 8                |
| Robertson, Tomothy  | 95          | 95          | 89          |                  |
| Cooper, Bruce       | 95          | 94          | 94          |                  |
| (Unnamed)           | 94          | 93          | 99          |                  |
| (Unnamed)           | 94          | 94          | 94          |                  |
| (Unnamed)           | 94          | 80          |             |                  |

Confidential 19

## Slide 20: Clarify differentiates by delivering the most actionable insights

Clarify differentiates by delivering the most actionable insights

**Table: Clarify Differentiation vs. Competitors by Product Category**

| Feature | NETWORKS                                                              | REFERRALS                                                          | CARE                                                                                                                                                                                                                            | GROWTH                                                                                                                                                                                                                                                                  | VALUE                                                                                                                  | POPULATIONS                                                                                                                                                                                     |
| :------ | :-------------------------------------------------------------------- | :----------------------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Logos** | Inovalon, CareJourney, RowdMap, Innovaccer, CEDAR GATE, QUEST ANALYTICS | OPTUM, CareJourney, Trilliant Health, Innovaccer, SEE NUNA, embold | vizient 3M, CareJourney, ARCADIA, Milliman, Inovalon, embold                                                                                                                                                                      | OPTUM, TRUVEN, komodohealth, AETION, IQVIA, Symphony Health, PRAHEALTHSCIENCES COMPANY                                                                                                                                                                                  | Archway Health, OPTUM, Milliman, naviHealth, innovaccer, NUNA, PREMIER                                                 | OPTUM, HealthCatalyst, ARCADIA, Lightbeam Health Solutions                                                                                                                              |
| **Key Differentiators** | *   Lack robust / on-the-fly analytics (Care Journey, Lightbeam, Cedar Gate) <br> *   Needs customer data (Arcadia, Rowdmap, Innovaccer) <br> *   Not holistic network tool (Inovalon – RAF, Quest - Adequacy) | *   Limited visibility into full journey / needs customer data (Trilliant, Sg2) <br> *   Weak/inflexible provider attribution (Embold, Optum¹) <br> *   No ML / AI in analytics (Optum, Nuna, Embold)                         | *   Case mix adj. not at patient/metric level (low actionability) <br> *   Low/no metric customizability <br> *   Only benchmark within the customer (Arcadia, Milliman) <br> *   Narrow expertise (Vizient – AMCs, Truven - data vendor, Milliman – actuarial) | *   Limited data (IQVIA & Symphony – pharmacy, Aetion – customer data) <br> *   Inflexible grouper (Komodo, Truven, Optum) <br> *   Black box / low customizability (Komodo, Optum) <br> *   No SBDoH (all comps) | *   Lack of patient & metric level case mix adj. (Nuna, Archway, Milliman, Navi) <br> *   Limited out-of-customer data (All) <br> *   Primarily services offering (Premier) <br> *   Point solution not platform (Archway, Navi) | *   No SBDoH <br> *   Analytics aggregated at a high level; does not get down to the patient <br> *   Low customizability to create metrics of interest to customer <br> *   Small data set or large services model (Arcadia, Lightbeam) |

1.  Crimson Market Advantage

Confidential 20

## Slide 21: Platform is based on patented technology

Platform is based on patented technology
Patents detail Clarify's predictive models and network architecture used to automate the creation of superior analytic insights

**Patents Status:**
*   **1st patent filed:** Jan 2018
*   **5 patents issued**
*   **10 additional patents in process**

**Patents cover areas including:**
*   Architecture powering automated machine learning model generation
*   Automating the creation of healthcare-specific performance benchmarks
*   Automatic identification of areas of under- and over-performance
*   Prevent some causes of poorly performing case-mix adjustment models
*   Continual application of machine learning models for patient guidance
*   Distill claims, SBDoH, EHR, and other data into analyzable, standardized units
*   Imputation of missing data in healthcare claims
*   Clarify's case-mix adjustment capability
*   Incorporate customer-specific healthcare outcomes in Clarify's data lake
*   Standardize provider and facility performance reporting

**Platform Capabilities (Icons):**
*   Machine learning automation & scaling (for healthcare)
*   Real-time financial & quality forecasting (in healthcare)
*   Dynamic patient guidance

Confidential 21

## Slide 22: Clarify's leadership team combines best of SaaS & healthcare

Clarify's leadership team combines best of SaaS & healthcare

**Jean Drouin, MD**
Chief Executive Officer
*   Head of Healthcare IT and Digital Practice, McKinsey
*   CEO/Founder of McKinsey Healthcare Analytics

**Todd Gottula**
President, Chief Product Officer
*   CTO & EVP Development, Advent Software
*   Two successful SaaS exits ($2.7B and $270M)

**Manisha Gulati**
Chief Operating Officer
*   Partner, McKinsey & Co. – Life Sci, Payer, Provider, Digital
*   15+ years experience supporting HC¹ orgs

**Nadeem Ahmed**
Chief Commercial Officer
*   Salesforce Leader / Senior AVP for Cloud, SAS, AI, Voice, Consumerism
*   20+ years responsible for Enterprise Select Segment for NA Healthcare and Life Sciences Business

**Nishta Giallorenzo**
Chief Marketing Officer
*   CMO, CipherHealth
*   Former Eli Lilly product leader
*   10+ years leading sales and marketing teams

**Justin Warner**
Chief Technology Officer
*   VP Development, Advent
*   Built global team of 100 engineers, analysts, QA, and designers

**Fred Bret-Mounet**
Chief Info. Security Officer
*   Information Security Officer, Syapse
*   15+ years in HC¹ information security (McKesson, Change Healthcare, Sapient)

**Ashley Clayborne**
VP, Head of Finance
*   Led FP&A at Dynamic Signal, McKesson;
*   Inv. banking at Morgan Stanley
*   United States Air Force, Harvard MBA, MIT BS

**Neechi Mosha, MD**
VP Strategy, Chief of Staff
*   Consultant, Health Care Payers, Providers & Services Expert, BCG
*   MIT MBA, Duke MD, Harvard BA

Confidential 22

## Slide 23: Investment thesis

Investment thesis

**RAPID REVENUE GROWTH**
Product-market fit established with industry leaders who are expanding their relationship with Clarify

**NETWORK EFFECT**
As data asset & customer base grows, we attract customers who are more willing to share their own data

**DISTINCTIVE TEAM**
20+ clinicians and healthcare operators
50+ software and data science experts

**HUGE MARKET**
$20B+ addressable market; $5B up for grabs annually from current products

**DISRUPTIVE TECH**
Products built with massive dataset combined with cutting edge analytics

Confidential 23